Compare iShares MSCI Singapore ETF (EWS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Organon & Co. Common Stock — how do they compare? iShares MSCI Singapore ETF trades at $31.22 (market cap $1.23B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 2.9× iShares MSCI Singapore ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MSCI Singapore ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 47 Days and Organon & Co. Common Stock for 0 Days on average.
| EWS | OGN | |
|---|---|---|
Market Cap | $1.23B | $3.62B |
Volume | 3,153,173 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $13.81 |
52-Week Low | $26.71 | $5.70 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $31.54, down slightly by 0.03% on the day. Technical indicators are mixed, with moving averages signaling a bearish trend while oscillators suggest potential oversold conditions. The ETF recently hit a 52-week high, driven by Singapore's strong economic growth and AI momentum. Institutional interest is positive, with Amundi increasing its stake by 4.8% as of its latest 13F filing.
The outlook for EWS is cautiously optimistic, supported by Singapore's resilient economy and institutional inflows. Key risks include stretched valuations after the multi-year rally and sensitivity to regional economic shifts. Investors should weigh the strong momentum against potential pullbacks in a high-valuation environment.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
